B of A Securities Reiterates Buy on Beam Therapeutics, Maintains $47 Price Target
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsReiterationPrice Target
B of A Securities analyst Alec Stranahan reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $47 price target.
B of A Securities analyst Alec Stranahan reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $47 price target.